The Stocks in Action || How S&P/ASX200 Performed As The US Bluechip Stocks Were On The Move?

This is The Stocks in Action show. First, let's look at ASX 200 and the ASX listed stocks that are trending today.  

• The benchmark index ASX 200 is up today, gaining 0.29 per cent to 7302.90 and setting a new 52-week high. The top performing stocks in this index are Mesoblast, up 5.65 per cent and Invocare, up 4.54 per cent. Over the last five days, the index has gained 2.24 per cent and is currently 0.17 per cent off of its 52-week high. 

• 9 of 11 sectors are higher along with the S&P/ASX 200 Index. A-REIT is the best performing sector, gaining 1.00 per cent and 4.83 per cent for the past five days. 

• The S&P/ASX 200 closed its session 0.19 per cent lower at 7,281.9, yesterday, on Monday, ending its three-day winning streak. However, before closing lower, the ASX 200 touched a new all-time high of 7,309.4.   

• The Aussie closed 0.4 per cent lower after gaining 1.04 per cent on Friday, while the New Zealand dollar was up by 0.2 per cent. 

• In the Cryptocurrency market, Bitcoin again fell below US$35,000 and is currently trading 4.4 per cent down, at US$34,191, the lowest level in June. Dogecoin is also down 9.5 per cent and Ethereum down 4.3 per cent (as of 7:16 AM AEST). 

• Crude oil prices slipped on Monday after reaching two-year high levels on OPEC's decision to curb production and an improved economic recovery leading to robust energy demand. 

• August delivery Brent crude oil futures traded flat at US$71.47 per barrel and WTI crude oil futures for July delivery traded 0.04 per cent down at US$69.20 per barrel as of 8 June 2021 at 10:13 AM AEST.

• Mobilicom Limited announced it has successfully completed delivery of more than AU$1.8 million of products for the AU$2.3 million contract with a leading global drone supplier, following shipment of over 200 additional units of its Ground Controller System. 

• Happy Valley Nutrition Limited gains as much as 6.7 per cent to AU$0.160, hitting its highest since 22 March 2021. 

• Immutep Limited, the leading developer of LAG-3 related immunotherapy treatments for cancer and autoimmune disease, has just shared an update on its preclinical development pipeline. 

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK